Three upheld rulings in a day against one GLP‑1 prescriber. The pattern is the unlabelled post, not the price tile.

01What happened

On 8 April 2026 the ASA published three upheld rulings against Juniper Technologies UK Ltd, an online prescriber of weight-loss medicines. Three rulings against one company in a single morning is unusual. What the rulings describe is more unusual still.

In the first ruling, Juniper had engaged marketing professionals, based outside the UK and paid by the hour, to post in public Facebook groups for people using Mounjaro and Wegovy. One post in a group called “mounjaro ozempic wegovy weight loss support” opened “First-time Juniper customer here” and offered a £85 referral code. Another praised Juniper’s “lower wegovy price” against Mounjaro. Neither carried an ad label, and neither poster was a customer at all. The ASA found the posts were marketing communications under Juniper’s control, that they were not obviously identifiable as ads, and that naming Wegovy and Mounjaro promoted prescription-only medicines to the public. CAP 2.1, 2.3 and 12.12.

The two companion rulings, published the same day, covered paid Instagram ads and website content: prescription-only medicines promoted to the public, and an undue sense of urgency aimed at people considering medicated weight loss.

The complainant in the support-group case was CheqUp Health Ltd. A competitor, and one with its own upheld rulings from July and December 2025. The sector is now reading the database and reporting itself.

02The shared pattern

None of this turned on a price tile or a doctor photo. It turned on disguise. Content seeded into patient communities, written to read as testimony, with the commercial relationship hidden.

Juniper told the ASA it had already ended the arrangement before the complaint reached it. That did not change the outcome. The rulings attach to what was published, not to what was later regretted.

03Where the line moves next

The same week's context matters. On 2 April CAP published an Enforcement Report covering its weight-loss POM programme: 18 rulings since 2025, around 900 ads likely to breach the rules from 38 of the 44 advertisers monitored, and compliance among monitored paid-for ads now near 99%. The paid channel has largely been brought to heel.

Two risks remain open in CAP’s own words. Non-paid content, especially influencer and affiliate advertising, where these rulings sit. And “grey area” approaches such as promotional pricing, where the ASA says investigations are ongoing. Pricing surfaces are the next front. They have not yet produced published rulings; do not wait until they do.

MHRA is moving in parallel. Its May 2026 list, published on 8 June, names three more businesses made to amend advertising over indirect references to weight-loss injections or GLP‑1 medication, on the basis that an ad is prohibited if it is likely to lead a member of the public to request a prescription-only medicine.

04Takeaway

If a growth channel only works because it does not look like advertising, that is now exactly where the rulings land. Seeded posts, affiliate content and unlabelled testimony in patient groups carry the same CAP 12.12 exposure as a paid ad, plus a disclosure breach on top. And the complaint that triggers the investigation may well come from the funnel one tab over.

Sources: ASA ruling A25-1314325, A25-1319597 and A25-1321384 (8 April 2026). CAP Enforcement Report and consumer research (2 April 2026). Joint Enforcement Notice, MHRA, ASA and GPhC (23 September 2025). MHRA, websites offering medicinal treatment services for weight loss, May 2026. CAP Code Section 12. Human Medicines Regulations 2012, regulation 284.